

HArmonyCa[®] Aftercare



24–48 h

Treatment-site reactions may typically resolve within 24–48 hours, and swelling within a week.¹



Application of an *ice pack or cold compresses* to the treated area for 24 hours post treatment can reduce redness, swelling, and irritation.¹



If small bumps under the skin (nodules) appear, you should *massage the treated area*.¹

Model has not been treated with HArmonyCa[®].

The information in this document is applicable only to receiving treatment with HArmonyCa®. If you have received treatment with any other product, speak with your healthcare professional about appropriate aftercare and other considerations related to that product.



Your healthcare professional will provide all pre- and post-treatment advice.

As a reminder:

Model has not been treated with HArmonyCa®.



Aftercare

As with all transcutaneous procedures, injection of HArmonyCa® carries a risk of infection. To reduce this risk, common practice of such procedures should be followed:



You should avoid strenuous activity and exposure to sunlight and tanning lamps or extreme weather conditions for 24 hours post-treatment in order to reduce redness, swelling, and irritation.¹



Application of an *ice pack* or *cold compresses* to the treated area for 24 hours post treatment can reduce redness, swelling, and irritation.¹



If small bumps under the skin (nodules) appear, you should *massage the treated area*.¹



The injected material may be palpable for a long period after treatment.¹



Common postoperative adverse events include erythema (redness), edema (swelling), pain, tenderness, itching, lumps or bumps, firmness, bruising, and discoloration.¹



Less common adverse events associated with dermal fillers in general and calcium hydroxyapatite-based fillers in particular include hematoma (bruising), seroma (accumulation of fluid under the skin), extrusion (misshaping due to force), induration (hardening), skin pigmentation, fistula formation, inflammatory reaction, infection, allergic reaction, migration, persistent nodules (small bumps), granulomas (small area of inflammation), fever, necrosis (cell death), and blindness.¹



Promptly report any common adverse event which doesn't resolve within the typical time frame, or which worsens, or any other adverse event to your healthcare professional!¹

Adverse events should be reported to Allergan Aesthetics, an AbbVie company, by emailing AGN-DL-AUSDermalInternationalComplaints@abbvie.com, or by calling 1-800-624-4261.

Reference: 1. Allergan Aesthetics. HArmonyCa® Lidocaine DFU. November 14, 2025.

HArmonyCa® is a trademark of Allergan, Inc., an AbbVie company.
All rights reserved. © 2026 AbbVie.
CA-HAR-260020

Allergan Aesthetics
an AbbVie company